New immune cell therapy takes on Hard-to-Treat stomach cancer
NCT ID NCT07333820
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called AB-201 for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has stopped responding to standard therapies. AB-201 uses specially designed immune cells (CAR-NK cells) to target and kill cancer cells. The main goal is to check the treatment's safety in 18 adults, with a secondary goal of seeing if it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF STOMACH, UNSPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
minkyu Jung
Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.